The disclosure relates to a pharmaceutical composition for oral contraception containing a gestagen selected from the group consisting of 17a-cyanomethyl-17beta-hydroxyestra-4,9-dien-3-one (dienogest), chlormadinone acetate and Levonorgestrel, in combination with an estrogen selected from the group consisting of synthetic estrogens and natural estrogens, wherein the synthetic estrogen may be ethinylestradiol and the natural estrogen may be selected from 17beta-estradiol (estradiol) or estradiol valerate, wherein microcrystalline cellulose is used as filler, the gestagens and estrogens are granulated with binders in an amount of 1-5% by mass of the pharmaceutical composition, and no lactose is included in the composition.
